Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Diabetology International
Erschienen in:

11.09.2024 | Review Article

Type 1 diabetes: immune pathology and novel therapeutic approaches

verfasst von: Eleanor M. Ling, Joana R. N. Lemos, Khemraj Hirani, Matthias von Herrath

Erschienen in: Diabetology International | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Type 1 diabetes (T1D) is characterized by the progressive destruction of insulin-producing beta cells in the pancreas. Despite improvements in insulin monitoring techniques, there remains no cure for T1D. Individuals with T1D require lifelong insulin therapy and some develop life-threatening complications. T1D is a complex, multifactorial, autoimmune condition. Understanding why people get T1D and how it progresses has advanced our knowledge of the disease and led to the discovery of specific targets that can be therapeutically manipulated to halt or reverse the course of T1D. Scientists investigating the potential of immunotherapy treatment for the treatment have recently had some encouraging results. Teplizumab, an anti-CD3 monoclonal antibody that has been approved by the FDA, delays the onset of clinical T1D in patients ≥ 8 years of age with preclinical T1D and improves beta cell function. Therapies targeting beta cell health, vitality, and function are now thought to be an essential component of successful combination therapy for T1D. The idea that the beta cells themselves may influence their own destruction during the development of T1D is a notion that has recently been gaining acceptance in the field. Researchers have recently made remarkable strides in beta cell replacement therapy and beta cell regeneration techniques. This review offers a detailed exploration of the pathophysiological mechanisms of T1D. It discusses the intricate interplay of factors leading to T1D development and the innovative approaches being explored to discover new treatments and a cure for the millions of people living with T1D worldwide.
Literatur
1.
Jeyagaran A, Lu CE, Zbinden A, Birkenfeld AL, Brucker SY, Layland SL. Type 1 diabetes and engineering enhanced islet transplantation. Adv Drug Deliv Rev. 2022;189: 114481.PubMedCrossRef
2.
3.
Janzen KM, Steuber TD, Nisly SA. GLP-1 agonists in Type 1 diabetes mellitus. Ann Pharmacother. 2016;50:656–65.PubMedCrossRef
4.
Burganova G, Bridges C, Thorn P, Landsman L. The role of vascular cells in pancreatic beta-cell function. Front Endocrinol (Lausanne). 2021;12: 667170.PubMedCrossRef
5.
6.
7.
Leete P. Type 1 diabetes in the pancreas: a histological perspective. Diabet Med. 2023;40: e15228.PubMedCrossRef
8.
9.
Benkahla MA, Sabouri S, Kiosses WB, Rajendran S, Quesada-Masachs E, von Herrath MG. HLA class I hyper-expression unmasks beta cells but not alpha cells to the immune system in pre-diabetes. J Autoimmun. 2021;119: 102628.PubMedPubMedCentralCrossRef
10.
Richardson SJ, Rodriguez-Calvo T, Gerling IC, Mathews CE, Kaddis JS, Russell MA, Zeissler M, Leete P, Krogvold L, Dahl-Jorgensen K, von Herrath M, Pugliese A, Atkinson MA, Morgan NG. Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia. 2016;59:2448–58.PubMedPubMedCentralCrossRef
11.
Dang MN, Buzzetti R, Pozzilli P. Epigenetics in autoimmune diseases with focus on type 1 diabetes. Diabetes Metab Res Rev. 2013;29:8–18.PubMedCrossRef
12.
Rakyan VK, Beyan H, Down TA, Hawa MI, Maslau S, Aden D, Daunay A, Busato F, Mein CA, Manfras B, Dias KR, Bell CG, Tost J, Boehm BO, Beck S, Leslie RD. Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet. 2011;7: e1002300.PubMedPubMedCentralCrossRef
13.
Stefan M, Zhang W, Concepcion E, Yi Z, Tomer Y. DNA methylation profiles in type 1 diabetes twins point to strong epigenetic effects on etiology. J Autoimmun. 2014;50:33–7.PubMedCrossRef
14.
Creusot RJ, Postigo-Fernandez J, Teteloshvili N. Altered function of antigen-presenting cells in type 1 diabetes: a challenge for antigen-specific immunotherapy? Diabetes. 2018;67:1481–94.PubMedPubMedCentralCrossRef
15.
Glisic-Milosavljevic S, Wang T, Koppen M, Kramer J, Ehlenbach S, Waukau J, Jailwala P, Jana S, Alemzadeh R, Ghosh S. Dynamic changes in CD4+ CD25+(high) T cell apoptosis after the diagnosis of type 1 diabetes. Clin Exp Immunol. 2007;150:75–82.PubMedPubMedCentralCrossRef
16.
Viisanen T, Gazali AM, Ihantola EL, Ekman I, Nanto-Salonen K, Veijola R, Toppari J, Knip M, Ilonen J, Kinnunen T. FOXP3+ regulatory T cell compartment is altered in children with newly diagnosed type 1 diabetes but not in autoantibody-positive at-risk children. Front Immunol. 2019;10:19.PubMedPubMedCentralCrossRef
17.
Luczynski W, Stasiak-Barmuta A, Wawrusiewicz-Kurylonek N, Kowalczuk O, Ilendo E, Glowinska-Olszewska B, Urban R, Szczepanski W, Urban M, Kretowski A, Chyczewski L. Disturbances in some gene expression in T regulatory cells separated from children with metabolic syndrome. Scand J Immunol. 2010;71:115–22.PubMedCrossRef
18.
Cabello-Kindelan C, Mackey S, Sands A, Rodriguez J, Vazquez C, Pugliese A, Bayer AL. Immunomodulation followed by antigen-specific T(reg) infusion controls islet autoimmunity. Diabetes. 2020;69:215–27.PubMedCrossRef
19.
Hope CM, Welch J, Mohandas A, Pederson S, Hill D, Gundsambuu B, Eastaff-Leung N, Grosse R, Bresatz S, Ang G, Papademetrios M, Zola H, Duhen T, Campbell D, Brown CY, Krumbiegel D, Sadlon T, Couper JJ, Barry SC. Peptidase inhibitor 16 identifies a human regulatory T-cell subset with reduced FOXP3 expression over the first year of recent onset type 1 diabetes. Eur J Immunol. 2019;49:1235–50.PubMedCrossRef
20.
Haseda F, Imagawa A, Murase-Mishiba Y, Terasaki J, Hanafusa T. CD4(+) CD45RA(-) FoxP3high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. Clin Exp Immunol. 2013;173:207–16.PubMedPubMedCentralCrossRef
21.
Putnam AL, Vendrame F, Dotta F, Gottlieb PA. CD4+CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun. 2005;24:55–62.PubMedCrossRef
22.
Ben-Skowronek I, Sieniawska J, Pach E, Wrobel W, Skowronek A, Tomczyk Z, Rosolowska I. Potential therapeutic application of regulatory T cells in diabetes mellitus type 1. Int J Mol Sci. 2021;23:390.PubMedPubMedCentralCrossRef
23.
Tuomilehto J, Ogle GD, Lund-Blix NA, Stene LC. Update on worldwide trends in occurrence of childhood type 1 diabetes in 2020. Pediatr Endocrinol Rev. 2020;17:198–209.PubMed
24.
Aarnisalo J, Veijola R, Vainionpaa R, Simell O, Knip M, Ilonen J. Cytomegalovirus infection in early infancy: risk of induction and progression of autoimmunity associated with type 1 diabetes. Diabetologia. 2008;51:769–72.PubMedCrossRef
25.
Oikarinen S, Tauriainen S, Hober D, Lucas B, Vazeou A, Sioofy-Khojine A, Bozas E, Muir P, Honkanen H, Ilonen J, Knip M, Keskinen P, Saha MT, Huhtala H, Stanway G, Bartsocas C, Ludvigsson J, Taylor K, Hyoty H, VirDiab Study G. Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes. Diabetes. 2014;63:655–62.PubMedCrossRef
26.
Alnek K, Talja I, Laht B, Metskula K, Mandel M, Reppo I, Lubi M, Uibo R. IgA-type enterovirus antibodies are increased among adults and children with recently diagnosed type 1 diabetes. Biomed Res Int. 2022;2022:7603062.PubMedPubMedCentralCrossRef
27.
Lemos JRN, Hirani K, von Herrath M. Immunological and virological triggers of type 1 diabetes: insights and implications. Front Immunol. 2023;14:1326711.PubMedCrossRef
28.
29.
30.
Rojas M, Restrepo-Jiménez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C, Leung PSC, Ansari AA, Gershwin ME, Anaya JM. Molecular mimicry and autoimmunity. J Autoimmun. 2018;95:100–23.PubMedCrossRef
31.
Hagopian WA, Lernmark A, Rewers MJ, Simell OG, She JX, Ziegler AG, Krischer JP, Akolkar B. TEDDY–the environmental determinants of diabetes in the young: an observational clinical trial. Ann N Y Acad Sci. 2006;1079:320–6.PubMedCrossRef
32.
Diabetes Prevention Trial-Type 1 Diabetes Study G. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346:1685–91.CrossRef
33.
Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L, Type 1 Diabetes TrialNet Study G. Type 1 diabetes trialnet–an international collaborative clinical trials network. Ann N Y Acad Sci. 2008;1150:14–24.PubMedPubMedCentralCrossRef
34.
Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark A, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine society, and the American diabetes association. Diabetes Care. 2015;38:1964–74.PubMedPubMedCentralCrossRef
35.
Achenbach P, Hummel M, Thumer L, Boerschmann H, Hofelmann D, Ziegler AG. Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children. Diabetologia. 2013;56:1615–22.PubMedCrossRef
36.
37.
Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, Knip M, Bonifacio E, Eisenbarth GS. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309:2473–9.PubMedPubMedCentralCrossRef
38.
Jia X, Gu Y, High H, Yu L. Islet autoantibodies in disease prediction and pathogenesis. Diabetol Int. 2020;11:6–10.PubMedCrossRef
39.
Anand V, Li Y, Liu B, Ghalwash M, Koski E, Ng K, Dunne JL, Jonsson J, Winkler C, Knip M, Toppari J, Ilonen J, Killian MB, Frohnert BI, Lundgren M, Ziegler AG, Hagopian W, Veijola R, Rewers M, Group TDS. Islet autoimmunity and HLA markers of presymptomatic and clinical type 1 diabetes: joint analyses of prospective cohort studies in finland, Germany, Sweden, and the US. Diabetes Care. 2021;44:2269–76.PubMedPubMedCentralCrossRef
40.
Balzano-Nogueira L, Ramirez R, Zamkovaya T, Dailey J, Ardissone AN, Chamala S, Serrano-Quilez J, Rubio T, Haller MJ, Concannon P, Atkinson MA, Schatz DA, Triplett EW, Conesa A. Integrative analyses of TEDDY omics data reveal lipid metabolism abnormalities, increased intracellular ROS and heightened inflammation prior to autoimmunity for type 1 diabetes. Genome Biol. 2021;22:39.PubMedPubMedCentralCrossRef
41.
Holm LJ, Krogvold L, Hasselby JP, Kaur S, Claessens LA, Russell MA, Mathews CE, Hanssen KF, Morgan NG, Koeleman BPC, Roep BO, Gerling IC, Pociot F, Dahl-Jorgensen K, Buschard K. Abnormal islet sphingolipid metabolism in type 1 diabetes. Diabetologia. 2018;61:1650–61.PubMedPubMedCentralCrossRef
42.
Ludvigsson J, Cuthbertson D, Becker DJ, Kordonouri O, Aschemeier B, Pacaud D, Clarson C, Krischer JP, Knip M, Investigators T. Increasing plasma glucose before the development of type 1 diabetes-the TRIGR study. Pediatr Diabetes. 2021;22:974–81.PubMedPubMedCentralCrossRef
43.
Ludvigsson J. Why diabetes incidence increases–a unifying theory. Ann N Y Acad Sci. 2006;1079:374–82.PubMedCrossRef
44.
Lamichhane S, Sen P, Dickens AM, Krakstrom M, Ilonen J, Lempainen J, Hyoty H, Lahesmaa R, Veijola R, Toppari J, Hyotylainen T, Knip M, Oresic M. Circulating metabolic signatures of rapid and slow progression to type 1 diabetes in islet autoantibody-positive children. Front Endocrinol (Lausanne). 2023;14:1211015.PubMedCrossRef
45.
Helminen O, Aspholm S, Pokka T, Ilonen J, Simell O, Veijola R, Knip M. OGTT and random plasma glucose in the prediction of type 1 diabetes and time to diagnosis. Diabetologia. 2015;58:1787–96.PubMedCrossRef
46.
Steck AK, Johnson K, Barriga KJ, Miao D, Yu L, Hutton JC, Eisenbarth GS, Rewers MJ. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes Care. 2011;34:1397–9.PubMedPubMedCentralCrossRef
47.
Campbell-Thompson M, Wasserfall C, Montgomery EL, Atkinson MA, Kaddis JS. Pancreas organ weight in individuals with disease-associated autoantibodies at risk for type 1 diabetes. JAMA. 2012;308:2337–9.PubMedCrossRef
48.
Virostko J, Williams J, Hilmes M, Bowman C, Wright JJ, Du L, Kang H, Russell WE, Powers AC, Moore DJ. Pancreas volume declines during the first year after diagnosis of type 1 diabetes and exhibits altered diffusion at disease onset. Diabetes Care. 2019;42:248–57.PubMedCrossRef
49.
Campbell-Thompson ML, Filipp SL, Grajo JR, Nambam B, Beegle R, Middlebrooks EH, Gurka MJ, Atkinson MA, Schatz DA, Haller MJ. Relative pancreas volume is reduced in first-degree relatives of patients with type 1 diabetes. Diabetes Care. 2019;42:281–7.PubMedCrossRef
50.
Chiarelli F, Verrotti A, Altobelli E, Blasetti A, Morgese G. Size of the pancreas in type I diabetic children and adolescents. Diabetes Care. 1995;18:1505–6.PubMedCrossRef
51.
Fonseca V, Berger LA, Beckett AG, Dandona P. Size of pancreas in diabetes mellitus: a study based on ultrasound. Br Med J (Clin Res Ed). 1985;291:1240–1.PubMedCrossRef
52.
Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965;14:619–33.PubMedCrossRef
53.
Gaglia JL, Guimaraes AR, Harisinghani M, Turvey SE, Jackson R, Benoist C, Mathis D, Weissleder R. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest. 2011;121:442–5.PubMedCrossRef
54.
Williams AJ, Thrower SL, Sequeiros IM, Ward A, Bickerton AS, Triay JM, Callaway MP, Dayan CM. Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes. J Clin Endocrinol Metab. 2012;97:E2109–13.PubMedCrossRef
55.
56.
Alexandre-Heymann L, Mallone R, Boitard C, Scharfmann R, Larger E. Structure and function of the exocrine pancreas in patients with type 1 diabetes. Rev Endocr Metab Disord. 2019;20:129–49.PubMedCrossRef
57.
Wright JJ, Saunders DC, Dai C, Poffenberger G, Cairns B, Serreze DV, Harlan DM, Bottino R, Brissova M, Powers AC. Decreased pancreatic acinar cell number in type 1 diabetes. Diabetologia. 2020;63:1418–23.PubMedPubMedCentralCrossRef
58.
Skog O, Korsgren S, Melhus A, Korsgren O. Revisiting the notion of type 1 diabetes being a T-cell-mediated autoimmune disease. Curr Opin Endocrinol Diabetes Obes. 2013;20:118–23.PubMedCrossRef
59.
Korsgren S, Molin Y, Salmela K, Lundgren T, Melhus A, Korsgren O. On the etiology of type 1 diabetes: a new animal model signifying a decisive role for bacteria eliciting an adverse innate immunity response. Am J Pathol. 2012;181:1735–48.PubMedPubMedCentralCrossRef
60.
Foster TP, Bruggeman B, Campbell-Thompson M, Atkinson MA, Haller MJ, Schatz DA. Exocrine pancreas dysfunction in type 1 diabetes. Endocr Pract. 2020;26:1505–13.PubMedPubMedCentralCrossRef
61.
Jacobsen LM, Bocchino L, Evans-Molina C, DiMeglio L, Goland R, Wilson DM, Atkinson MA, Aye T, Russell WE, Wentworth JM, Boulware D, Geyer S, Sosenko JM. The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. Diabetologia. 2020;63:588–96.PubMedCrossRef
62.
Krischer JP, Lynch KF, Schatz DA, Ilonen J, Lernmark A, Hagopian WA, Rewers MJ, She JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Bonifacio E, Group TS. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia. 2015;58:980–7.PubMedPubMedCentralCrossRef
63.
Delong T, Wiles TA, Baker RL, Bradley B, Barbour G, Reisdorph R, Armstrong M, Powell RL, Reisdorph N, Kumar N, Elso CM, DeNicola M, Bottino R, Powers AC, Harlan DM, Kent SC, Mannering SI, Haskins K. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science. 2016;351:711–4.PubMedPubMedCentralCrossRef
64.
Babon JA, DeNicola ME, Blodgett DM, Crevecoeur I, Buttrick TS, Maehr R, Bottino R, Naji A, Kaddis J, Elyaman W, James EA, Haliyur R, Brissova M, Overbergh L, Mathieu C, Delong T, Haskins K, Pugliese A, Campbell-Thompson M, Mathews C, Atkinson MA, Powers AC, Harlan DM, Kent SC. Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat Med. 2016;22:1482–7.PubMedPubMedCentralCrossRef
65.
Mitchell AM, Alkanani AA, McDaniel KA, Pyle L, Waugh K, Steck AK, Nakayama M, Yu L, Gottlieb PA, Rewers MJ, Michels AW. T-cell responses to hybrid insulin peptides prior to type 1 diabetes development. Proc Natl Acad Sci U S A. 2021;118(6):e2019129118.PubMedPubMedCentralCrossRef
66.
Morgan NG, Leete P, Foulis AK, Richardson SJ. Islet inflammation in human type 1 diabetes mellitus. IUBMB Life. 2014;66:723–34.PubMedCrossRef
67.
Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009;155:173–81.PubMedPubMedCentralCrossRef
68.
Arif S, Leete P, Nguyen V, Marks K, Nor NM, Estorninho M, Kronenberg-Versteeg D, Bingley PJ, Todd JA, Guy C, Dunger DB, Powrie J, Willcox A, Foulis AK, Richardson SJ, de Rinaldis E, Morgan NG, Lorenc A, Peakman M. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes. 2014;63:3835–45.PubMedPubMedCentralCrossRef
69.
Leete P, Willcox A, Krogvold L, Dahl-Jorgensen K, Foulis AK, Richardson SJ, Morgan NG. Differential insulitic profiles determine the extent of beta-cell destruction and the age at onset of type 1 diabetes. Diabetes. 2016;65:1362–9.PubMedCrossRef
70.
Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. Current concepts on the pathogenesis of type 1 diabetes–considerations for attempts to prevent and reverse the disease. Diabetes Care. 2015;38:979–88.PubMedPubMedCentralCrossRef
71.
Rodriguez-Calvo T, Suwandi JS, Amirian N, Zapardiel-Gonzalo J, Anquetil F, Sabouri S, von Herrath MG. Heterogeneity and lobularity of pancreatic pathology in type 1 diabetes during the prediabetic phase. J Histochem Cytochem. 2015;63:626–36.PubMedPubMedCentralCrossRef
72.
Richardson SJ, Willcox A, Bone AJ, Morgan NG, Foulis AK. Immunopathology of the human pancreas in type-I diabetes. Semin Immunopathol. 2011;33:9–21.PubMedCrossRef
73.
Richardson SJ, Morgan NG, Foulis AK. Pancreatic pathology in type 1 diabetes mellitus. Endocr Pathol. 2014;25:80–92.PubMedCrossRef
74.
Sherry NA, Tsai EB, Herold KC. Natural history of beta-cell function in type 1 diabetes. Diabetes. 2005;54(Suppl 2):S32–9.PubMedCrossRef
75.
Keymeulen B, Somers G. Immunointervention in type 1 (insulin-dependent) diabetes mellitus. Acta Clin Belg. 1993;48:86–95.PubMedCrossRef
76.
Muhammad BJ, Swift PG, Raymond NT, Botha JL. Partial remission phase of diabetes in children younger than age 10 years. Arch Dis Child. 1999;80:367–9.PubMedPubMedCentralCrossRef
77.
Bober E, Dundar B, Buyukgebiz A. Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab. 2001;14:435–41.PubMedCrossRef
78.
Buyukgebiz A, Cemeroglu AP, Bober E, Mohn A, Chiarelli F. Factors influencing remission phase in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2001;14:1585–96.PubMedCrossRef
79.
Lombardo F, Valenzise M, Wasniewska M, Messina MF, Ruggeri C, Arrigo T, De Luca F. Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis. Diabetes Nutr Metab. 2002;15:246–51.PubMed
80.
Abdul-Rasoul M, Habib H, Al-Khouly M. ‘The honeymoon phase’ in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes. 2006;7:101–7.PubMedCrossRef
81.
Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26:832–6.PubMedCrossRef
82.
Narsale A, Almanza F, Tran T, Lam B, Seo D, Vu A, Long SA, Cooney L, Serti E, Davies JD. Th2 cell clonal expansion at diagnosis in human type 1 diabetes. Clin Immunol. 2023;257:109829.PubMedCrossRef
83.
Lamichhane S, Kemppainen E, Trost K, Siljander H, Hyoty H, Ilonen J, Toppari J, Veijola R, Hyotylainen T, Knip M, Oresic M. Circulating metabolites in progression to islet autoimmunity and type 1 diabetes. Diabetologia. 2019;62:2287–97.PubMedPubMedCentralCrossRef
84.
Oresic M, Simell S, Sysi-Aho M, Nanto-Salonen K, Seppanen-Laakso T, Parikka V, Katajamaa M, Hekkala A, Mattila I, Keskinen P, Yetukuri L, Reinikainen A, Lahde J, Suortti T, Hakalax J, Simell T, Hyoty H, Veijola R, Ilonen J, Lahesmaa R, Knip M, Simell O. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med. 2008;205:2975–84.PubMedPubMedCentralCrossRef
85.
Lamichhane S, Ahonen L, Dyrlund TS, Kemppainen E, Siljander H, Hyoty H, Ilonen J, Toppari J, Veijola R, Hyotylainen T, Knip M, Oresic M. Dynamics of plasma lipidome in progression to islet autoimmunity and type 1 diabetes - type 1 diabetes prediction and prevention study (DIPP). Sci Rep. 2018;8:10635.PubMedPubMedCentralCrossRef
86.
Kupila A, Muona P, Simell T, Arvilommi P, Savolainen H, Hamalainen AM, Korhonen S, Kimpimaki T, Sjoroos M, Ilonen J, Knip M, Simell O, Juvenile Diabetes Research Foundation Centre for the Prevention of Type IDiF. Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort. Diabetologia. 2001;44:290–7.PubMedCrossRef
87.
Galderisi A, Pirillo P, Moret V, Stocchero M, Gucciardi A, Perilongo G, Moretti C, Monciotti C, Giordano G, Baraldi E. Metabolomics reveals new metabolic perturbations in children with type 1 diabetes. Pediatr Diabetes. 2018;19:59–67.PubMedCrossRef
88.
Balderas C, Ruperez FJ, Ibanez E, Senorans J, Guerrero-Fernandez J, Casado IG, Gracia-Bouthelier R, Garcia A, Barbas C. Plasma and urine metabolic fingerprinting of type 1 diabetic children. Electrophoresis. 2013;34:2882–90.PubMedCrossRef
89.
Vatanen T, Franzosa EA, Schwager R, Tripathi S, Arthur TD, Vehik K, Lernmark A, Hagopian WA, Rewers MJ, She JX, Toppari J, Ziegler AG, Akolkar B, Krischer JP, Stewart CJ, Ajami NJ, Petrosino JF, Gevers D, Lahdesmaki H, Vlamakis H, Huttenhower C, Xavier RJ. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature. 2018;562:589–94.PubMedPubMedCentralCrossRef
90.
Vatanen T, Kostic AD, d’Hennezel E, Siljander H, Franzosa EA, Yassour M, Kolde R, Vlamakis H, Arthur TD, Hamalainen AM, Peet A, Tillmann V, Uibo R, Mokurov S, Dorshakova N, Ilonen J, Virtanen SM, Szabo SJ, Porter JA, Lahdesmaki H, Huttenhower C, Gevers D, Cullen TW, Knip M, Xavier RJ, Group DS. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell. 2016;165:1551.PubMedCrossRef
91.
Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol. 2016;12:154–67.PubMedCrossRef
92.
93.
Hubbard TD, Murray IA, Bisson WH, Lahoti TS, Gowda K, Amin SG, Patterson AD, Perdew GH. Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. Sci Rep. 2015;5:12689.PubMedPubMedCentralCrossRef
94.
Alexeev EE, Lanis JM, Kao DJ, Campbell EL, Kelly CJ, Battista KD, Gerich ME, Jenkins BR, Walk ST, Kominsky DJ, Colgan SP. Microbiota-derived indole metabolites promote human and murine intestinal homeostasis through regulation of interleukin-10 receptor. Am J Pathol. 2018;188:1183–94.PubMedPubMedCentralCrossRef
95.
Kurpiewska E, Ciezki S, Jamiolkowska-Sztabkowska M, Polkowska A, Starosz A, Grubczak K, Moniuszko M, Bossowski A, Glowinska-Olszewska B. Excessive BMI is associated with higher C-peptide level at recognition but also with its greater loss in two years clinical observation in children with new onset type 1 diabetes. Front Immunol. 2023;14:1176403.PubMedPubMedCentralCrossRef
96.
Szypowska A, Groele L, Wysocka-Mincewicz M, Mazur A, Lisowicz L, Ben-Skowronek I, Sieniawska J, Klonowska B, Charemska D, Nawrotek J, Jalowiec I, Bossowski A, Noiszewska K, Pyrzak B, Rogozinska I, Szalecki M. Factors associated with preservation of C-peptide levels at the diagnosis of type 1 diabetes. J Diabetes Complications. 2018;32:570–4.PubMedCrossRef
97.
Redondo MJ, Rodriguez LM, Escalante M, O’Brian Smith E, Balasubramanyam A, Haymond MW. Beta cell function and BMI in ethnically diverse children with newly diagnosed autoimmune type 1 diabetes. Pediatr Diabetes. 2012;13:564–71.PubMedCrossRef
98.
Lauria A, Barker A, Schloot N, Hosszufalusi N, Ludvigsson J, Mathieu C, Mauricio D, Nordwall M, Van der Schueren B, Mandrup-Poulsen T, Scherbaum WA, Weets I, Gorus FK, Wareham N, Leslie RD, Pozzilli P. BMI is an important driver of beta-cell loss in type 1 diabetes upon diagnosis in 10–18 year-old children. Eur J Endocrinol. 2015;172:107–13.PubMedCrossRef
99.
Op de Beeck A, Eizirik DL. Viral infections in type 1 diabetes mellitus–why the beta cells? Nat Rev Endocrinol. 2016;12:263–73.PubMedCrossRef
100.
Jog NR, James JA. Epstein barr virus and autoimmune responses in systemic lupus erythematosus. Front Immunol. 2020;11: 623944.PubMedCrossRef
101.
102.
Pipeleers D, Ling Z. Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev. 1992;8:209–27.PubMedCrossRef
103.
Lernmark A, Kloppel G, Stenger D, Vathanaprida C, Falt K, Landin-Olsson M, Baskin DG, Palmer JP, Gown AM, Petersen JS, et al. Heterogeneity of islet pathology in two infants with recent onset diabetes mellitus. Virchows Arch. 1995;425:631–40.PubMedCrossRef
104.
American Diabetes Association Professional Practice C. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care 2024;47:S20-S42.
105.
Itariu BK, Stulnig TM. Autoimmune aspects of type 2 diabetes mellitus - a mini-review. Gerontology. 2014;60:189–96.PubMedCrossRef
106.
Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care. 2006;29:970–5.PubMedCrossRef
107.
Satomura A, Oikawa Y, Haisa A, Suzuki S, Nakanishi S, Katsuki T, Shimada A. Clinical significance of Insulin peptide-specific interferon-gamma-related immune responses in ketosis-prone type 2 diabetes. J Clin Endocrinol Metab. 2022;107:e2124–32.PubMedCrossRef
108.
Correction to New diagnostic criteria. For slowly progressive type 1 diabetes (SPIDDM): report from committee on type 1 diabetes of the Japan diabetes society (english version). J Diabetes Investig. 2023;2024(15):643.
109.
Redondo MJ, Morgan NG. Heterogeneity and endotypes in type 1 diabetes mellitus. Nat Rev Endocrinol. 2023;19:542–54.PubMedCrossRef
110.
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98–107.PubMedCrossRef
111.
Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnstrom BO, Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR, Groop LC. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes. 1999;48:150–7.PubMedCrossRef
112.
Luo S, Ma X, Li X, Xie Z, Zhou Z. Fulminant type 1 diabetes: a comprehensive review of an autoimmune condition. Diabetes Metab Res Rev. 2020;36: e3317.PubMedCrossRef
113.
Chujo D, Kawabe A, Matsushita M, Tsutsumi C, Haseda F, Imagawa A, Hanafusa T, Ueki K, Kajio H, Yagi K, Tobe K, Shimoda M. Fulminant type 1 diabetes patients display high frequencies of IGRP-specific type 1 CD8(+) T cells. Clin Immunol. 2021;233: 108893.PubMedCrossRef
114.
Imagawa A. Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor-related and conventional. J Diabetes Investig. 2021;12:917–9.PubMedCrossRef
115.
Cho YK, Jung CH. Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice. Diabetes Metab J. 2023;47:757–66.PubMedPubMedCentralCrossRef
116.
Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab. 2007;3(1):36–45.PubMedCrossRef
117.
Imagawa A, Hanafusa T. Fulminant type 1 diabetes–an important subtype in East Asia. Diabetes Metab Res Rev. 2011;27:959–64.PubMedCrossRef
118.
Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide diabetes mondiale (DiaMond). Diabetes Care. 2000;23(10):1516–26.PubMedCrossRef
119.
Moreau C, Drui D, Arnault-Ouary G, Charbonnel B, Chaillous L, Cariou B. Fulminant type 1 diabetes in caucasians: a report of three cases. Diabetes Metab. 2008;34:529–32.PubMedCrossRef
120.
Kawabata Y, Nishida N, Awata T, Kawasaki E, Imagawa A, Shimada A, Osawa H, Tanaka S, Takahashi K, Nagata M, Yasuda H, Uchigata Y, Kajio H, Makino H, Yasuda K, Kobayashi T, Hanafusa T, Tokunaga K, Ikegami H. Genome-wide association study confirming a strong effect of HLA and identifying variants in CSAD/lnc-ITGB7–1 on chromosome 12q13.13 associated with susceptibility to fulminant type 1 diabetes. Diabetes. 2019;68:665–75.PubMedCrossRef
121.
Toren E, Burnette KS, Banerjee RR, Hunter CS, Tse HM. Partners in crime: beta-cells and autoimmune responses complicit in type 1 diabetes pathogenesis. Front Immunol. 2021;12: 756548.PubMedPubMedCentralCrossRef
122.
Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M. Understanding and preventing type 1 diabetes through the unique working model of TrialNet. Diabetologia. 2017;60:2139–47.PubMedPubMedCentralCrossRef
123.
Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine society, and the American diabetes association. Diabetes Care. 2015;38:1964–74.PubMedPubMedCentralCrossRef
124.
125.
Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, Rhodes CJ. How does type 1 diabetes develop?: the notion of homicide or beta-cell suicide revisited. Diabetes. 2011;60:1370–9.PubMedPubMedCentralCrossRef
126.
Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the beta-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021;17:150–61.PubMedCrossRef
127.
Azoury ME, Tarayrah M, Afonso G, Pais A, Colli ML, Maillard C, Lavaud C, Alexandre-Heymann L, Gonzalez-Duque S, Verdier Y, Vinh J, Pinto S, Buus S, Dubois-Laforgue D, Larger E, Beressi JP, Bruno G, Eizirik DL, You S, Mallone R. Peptides derived from insulin granule proteins are targeted by CD8(+) T cells across MHC class I restrictions in humans and NOD mice. Diabetes. 2020;69:2678–90.PubMedCrossRef
128.
Gonzalez-Duque S, Azoury ME, Colli ML, Afonso G, Turatsinze JV, Nigi L, Lalanne AI, Sebastiani G, Carré A, Pinto S, Culina S, Corcos N, Bugliani M, Marchetti P, Armanet M, Diedisheim M, Kyewski B, Steinmetz LM, Buus S, You S, Dubois-Laforgue D, Larger E, Beressi JP, Bruno G, Dotta F, Scharfmann R, Eizirik DL, Verdier Y, Vinh J, Mallone R. Conventional and neo-antigenic peptides presented by β cells are targeted by circulating naïve CD8+ T cells in type 1 diabetic and healthy donors. Cell Metab. 2018;28:946–960.e6.PubMedCrossRef
129.
Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021;17:150–61.PubMedCrossRef
130.
Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swensen AC, Yip-Schneider M, Schmidt CM, Considine RV, Arvan P, Greenbaum CJ, Evans-Molina C. Proinsulin secretion is a persistent feature of type 1 diabetes. Diabetes Care. 2019;42:258–64.PubMedCrossRef
131.
Wasserfall C, Nick HS, Campbell-Thompson M, Beachy D, Haataja L, Kusmartseva I, Posgai A, Beery M, Rhodes C, Bonifacio E, Arvan P, Atkinson M. Persistence of pancreatic insulin mRNA expression and proinsulin protein in type 1 diabetes pancreata. Cell Metab. 2017;26:568–575.e3.PubMedPubMedCentralCrossRef
132.
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ, Type 1 Diabetes TrialNet Study G. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381:603–13.PubMedPubMedCentralCrossRef
133.
Kamrul-Hasan ABM, Mondal S, Nagendra L, Yadav A, Aalpona FTZ, Dutta D. Role of teplizumab, a humanized anti-CD3 monoclonal antibody, in managing newly diagnosed type 1 Diabetes: an updated systematic review and meta-analysis. Endocr Pract. 2024;30:431–40.PubMedCrossRef
134.
Calderon Martinez E, Castillo JL, Zachariah Saji S, Stein D, Khan TJ, Guardado Williams RF, Munguia ID, Arruarana VS, Velasquez K. Insulin pump therapy vs multiple daily insulin injections for glycemic control in children with type 1 diabetes: a systematic review and meta-analysis. Cureus. 2024;16: e52054.PubMedPubMedCentral
135.
Wake AD. Protective effects of physical activity against health risks associated with type 1 diabetes: “health benefits outweigh the risks.” World J Diabetes. 2022;13:161–84.PubMedPubMedCentralCrossRef
136.
Mullard A. FDA approves first cell therapy for type 1 diabetes. Nat Rev Drug Discov. 2023;22:611.PubMed
137.
Quattrin T, Haller MJ, Steck AK, Felner EI, Li Y, Xia Y, Leu JH, Zoka R, Hedrick JA, Rigby MR, Vercruysse F, Investigators TGS. Golimumab and beta-cell function in youth with new-onset type 1 diabetes. N Engl J Med. 2020;383:2007–17.PubMedCrossRef
138.
Waibel M, Wentworth JM, So M, Couper JJ, Cameron FJ, MacIsaac RJ, Atlas G, Gorelik A, Litwak S, Sanz-Villanueva L, Trivedi P, Ahmed S, Martin FJ, Doyle ME, Harbison JE, Hall C, Krishnamurthy B, Colman PG, Harrison LC, Thomas HE, Kay TWH, Group BS. Baricitinib and beta-cell function in patients with new-onset type 1 diabetes. N Engl J Med. 2023;389:2140–50.PubMedCrossRef
139.
140.
von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, Gumprecht J, Hansen TK, Mathieu C, Morales C, Mosenzon O, Segel S, Tsoukas G, Pieber TR, Anti ILlSGi, contributors. Anti-interleukin-21 antibody and liraglutide for the preservation of beta-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021;9:212–24.CrossRef
141.
142.
Yesildag B, Mir-Coll J, Neelakandhan A, Gibson CB, Perdue NR, Rufer C, Karsai M, Biernath A, Forschler F, Jin PW, Misun PM, Title A, Hierlemann A, Kreiner FF, Wesley JD, von Herrath MG. Liraglutide protects beta-cells in novel human islet spheroid models of type 1 diabetes. Clin Immunol. 2022;244: 109118.PubMedCrossRef
143.
Dutta D, Nagendra L, Raizada N, Bhattacharya S, Sharma M. Verapamil improves one-year C-peptide levels in recent onset type-1 diabetes: a meta-analysis. Indian J Endocrinol Metab. 2023;27:192–200.PubMedPubMedCentralCrossRef
144.
Foster TP, Jacobsen LM, Bruggeman B, Salmon C, Hosford J, Chen A, Cintron M, Mathews CE, Wasserfall C, Brusko MA, Brusko TM, Atkinson MA, Schatz DA, Haller MJ. Low-dose antithymocyte globulin: a pragmatic approach to treating stage 2 type 1 diabetes. Diabetes Care. 2024;47:285–9.PubMedCrossRef
145.
Metadaten
Titel
Type 1 diabetes: immune pathology and novel therapeutic approaches
verfasst von
Eleanor M. Ling
Joana R. N. Lemos
Khemraj Hirani
Matthias von Herrath
Publikationsdatum
11.09.2024
Verlag
Springer Nature Singapore
Erschienen in
Diabetology International / Ausgabe 4/2024
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-024-00748-z

Weitere Artikel der Ausgabe 4/2024

Causes of death in Japanese patients with diabetes based on the results of survey of 68,555 cases during 2011–2020: committee report on causes of death in diabetes mellitus, Japan Diabetes Society (English version)

  • Report of the Committee

The comorbidity burden of type 2 diabetes mellitus (T2DM): sex differences and associated factors among 830 cases in North-Eastern Morocco

  • Original Article

Monogenic diabetes

  • Mini-Review

General aspects of genetic studies on diabetes mellitus

  • Introduction to Mini-Reviews

Calculated estimation of the metabolic clearance rate of insulin measured by glucose clamp examination in out-patient clinical practice

  • Short Communication

Healthy lifestyle factors as predictors of the initiation of dialysis in people with and without diabetes

  • Original Article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

Schützt das tägliche Glas Milch vor Darmkrebs?

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise